Efficacy of ART to Interrupt HIV Transmission Networks (ART-NET)

The investigators are conducting a study to learn more about the spread of HIV infection within different geographic regions and populations in San Diego County, with the goal of demonstrating that early use of HIV treatment can reduce the number of new infections in our community. At the study visits, participants will be examined by the study staff and asked to donate some blood. Participants will also be asked several questions about themselves, their background, behaviors, health, and the general geographic area in which they live. By collecting information about antiretroviral treatment choices that are made by study participants, the investigators will be better able to measure how effectively HIV treatment can interrupt (i.e., block) the spread of HIV. All of the information gathered at the study visits will be de-identified and analyzed. Study staff will use the information to better understand in which groups of people, and in what areas of San Diego, HIV is spreading most quickly. This information will be used to determine how well Antiretroviral Therapy (HIV treatment) by certain individuals can control the spread of HIV within the population.

Study Overview

• Status: Completed
• Conditions: HIV

• Study Type: Observational
• Enrollment (Actual): 256

Contacts and Locations

Study Locations

• United States
  • California
    • San Diego, California, United States, 92103
      • UCSD Antiviral Research Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Persons with newly diagnosed HIV infection

Description

Inclusion Criteria:

1. Age ≥18 years of age
2. Newly diagnosed HIV infection
3. ART naïve (≤7 days ART, previous use of PEP or PrEP are not exclusions)
4. Subject must be able to provide written consent
5. Subject must agree to study specific specimen collections and visit schedule.
6. Subjects with newly diagnosed HIV infection who were identified on or after May 1, 2014 will be eligible for enrollment as long as they are co-enrolled to either AEH020 (project 08-0278) or AEH030 (project 140093) and DID meet the above study inclusion criteria (items at the time of enrollment to protocols AEH020 or AEH030).

Exclusion Criteria:

1. Any factor or factors that in the opinion of the local investigator that could prevent compliance with study requirements.
2. Contraindication to phlebotomy or specimen collection.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
HIV positive; Persons newly diagnosed with HIV.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Network-level efficacy of ART as measured by the number of newly infected persons and network cluster growth over time	5 Years

Collaborators and Investigators

• Sponsor: University of California, San Diego
• Investigators: Principal Investigator: Susan J Little, MD, UCSD

Publications and helpful links

Helpful Links

• AntiViral Research Center website

Study record dates

Study Major Dates

• Study Start (Actual): September 9, 2014
• Primary Completion (Actual): February 14, 2020
• Study Completion (Actual): February 14, 2020

Study Registration Dates

• First Submitted: May 13, 2015
• First Submitted That Met QC Criteria: August 17, 2015
• First Posted (Estimate): August 19, 2015

Study Record Updates

• Last Update Posted (Actual): November 4, 2020
• Last Update Submitted That Met QC Criteria: November 2, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Other Study ID Numbers: 141105